Investigation of Anti-melanoma Mechanisms and Targeted Delivery of Isoliquiritigenin

Project: Research project

Project Details


Malignant melanoma is an aggressive metastatic cancer. Current therapeutic drugs for melanoma are of low efficacy or have severe toxicities. Novel safe and effective drugs for treating melanoma are needed. We have found that isoliquiritigenin (ISL) has anti-melanoma effects. However, its anti-melanoma mechanisms are not fully understood. In addition, the solubility and bioavailability of ISL are poor. In this project, we will apply multi-omics approaches to comprehensively explore the anti-melanoma mechanisms of ISL, and will develop a melanoma-targeting ISL nanoliposome DSPE-PEG2000-FA/ISL. The outputs of this project will benefit melanoma patients.
Effective start/end date1/07/2330/06/25


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.